» Articles » PMID: 29946544

Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment

Overview
Specialty Cell Biology
Date 2018 Jun 28
PMID 29946544
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Historically, the link between chronic inflammation and cancer has long been speculated. Only more recently, pre-clinical and epidemiologic data as well as clinical evidence all point to the role of the tumor microenvironment as inextricably connected to the neoplastic process. The tumor microenvironment (TME), a complex mix of vasculature, inflammatory cells, and stromal cells is the essential "soil" helping to modulate tumor potential. Increasingly, evidence suggests that chronic inflammation modifies the tumor microenvironment, via a host of mechanisms, including the production of cytokines, pro-inflammatory mediators, angiogenesis, and tissue remodeling. Inflammation can be triggered by a variety of different pressures, such as carcinogen exposure, immune dysfunction, dietary habits, and obesity, as well as genetic alterations leading to oncogene activation or loss of tumor suppressors. In this review, we examine the concept of the tumor microenvironment as related to both extrinsic and intrinsic stimuli that promote chronic inflammation and in turn tumorigenesis. Understanding the common pathways inherent in an inflammatory response and the tumor microenvironment may shed light on new therapies for both primary and metastatic disease. The concept of personalized medicine has pushed the field of oncology to drill down on the genetic changes of a cancer, in the hopes of identifying individually targeted agents. Given the complexities of the tumor microenvironment, it is clear that effective oncologic therapies will necessitate targeting not only the cancer cells, but their dynamic relationship to the tumor microenvironment as well.

Citing Articles

Methylglyoxal Formation-Metabolic Routes and Consequences.

Vaskova J, Kovacova G, Pudelsky J, Palencar D, Mickova H Antioxidants (Basel). 2025; 14(2).

PMID: 40002398 PMC: 11852113. DOI: 10.3390/antiox14020212.


Ferroptosis Plays a Pivotal Role in Activating and Modulating Specific Intracellular Signaling Pathways Integrated into the Therapeutic Management of Colorectal Cancer.

Monemi M, Ahmed H, Kareem R, Taher W, Alwan M, Jawad M Int J Mol Cell Med. 2025; 13(4):374-386.

PMID: 39895914 PMC: 11786127. DOI: 10.22088/IJMCM.BUMS.13.4.374.


The systemic inflammation response index (SIRI) predicts survival in advanced non-small cell lung cancer patients undergoing immunotherapy and the construction of a nomogram model.

Tang C, Zhang M, Jia H, Wang T, Wu H, Xu K Front Immunol. 2025; 15():1516737.

PMID: 39776905 PMC: 11703897. DOI: 10.3389/fimmu.2024.1516737.


Nomogram model based on γ-glutamyl transferase to albumin ratio predicts survival in hepatocellular carcinoma patients with transarterial chemoembolization treatment.

Wu Z, Li H, Chen J, Su K, Weng M, Han Y World J Gastrointest Oncol. 2024; 16(12):4650-4662.

PMID: 39678787 PMC: 11577374. DOI: 10.4251/wjgo.v16.i12.4650.


Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

Morel K, German B, Hamid A, Nanda J, Linder S, Bergman A J Clin Invest. 2024; 135(2.

PMID: 39560993 PMC: 11735106. DOI: 10.1172/JCI175680.


References
1.
Franklin R, Liao W, Sarkar A, Kim M, Bivona M, Liu K . The cellular and molecular origin of tumor-associated macrophages. Science. 2014; 344(6186):921-5. PMC: 4204732. DOI: 10.1126/science.1252510. View

2.
Schafer M, Werner S . Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 2008; 9(8):628-38. DOI: 10.1038/nrm2455. View

3.
GREINER J, HAND P, Noguchi P, Fisher P, Pestka S, Schlom J . Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res. 1984; 44(8):3208-14. View

4.
Yan L, Anderson G, DeWitte M, Nakada M . Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer. 2006; 42(6):793-802. DOI: 10.1016/j.ejca.2006.01.013. View

5.
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder S . Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10):2062-8. PMC: 4854652. DOI: 10.1038/leu.2015.212. View